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The Nucleoporin RanBP2
Has SUMO1 E3 Ligase Activity
(Aos1/Uba2) and a single E2 conjugating enzyme (Ubc9)
have been identified in yeast and higher eukaryotes. In
vitro, these are sufficient to modify a number of SUMO1
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targets, including IB, RanGAP1, and p53, and it was1 Max-Planck Institute for Biochemistry
proposed that SUMO1 modification would not requireAm Klopferspitz 18a
E3 ligases (references in Hay, 2001; Melchior, 2000;82152 Martinsried
Mu¨ller et al., 2001). However, recently several SUMOGermany
E3-like factors were identified in yeast and mammalian2 Unite´ de Recombinaison et Expression Ge´ne´tique
cells (Johnson and Gupta, 2001; Kahyo et al., 2001;INSERM U163
Sachdev et al., 2001; Takahashi et al., 2001). These pro-Institut Pasteur
teins are different members of one family, the protein28 rue du Dr. Roux
inhibitors of activated STAT (PIAS). Saccharomyces ce-75724 Paris Cedex 15
revisiae Siz1 is involved in septin modification, PIAS1France
stimulates p53 modification, and PIASy enhances modi-
fication of Lef1.
Based on immunofluorescence studies, both subunitsSummary
of the SUMO1 E1 activating enzyme reside predomi-
nantly in the nucleus (Azuma et al., 2001; Rodriguez etPosttranslational modification with SUMO1 regulates
al., 2001). In addition, Ubc9 has been found in a complexprotein/protein interactions, localization, and stability.
with SUMO1-modified RanGAP1 and RanBP2 (Lee etSUMOylation requires the E1 enzyme Aos1/Uba2 and
al., 1998; Saitoh et al., 1997). Both proteins are compo-the E2 enzyme Ubc9. A family of E3-like factors, PIAS
nents of the nucleocytoplasmic transport machinery (re-proteins, was discovered recently. Here we show that
viewed in Go¨rlich and Kutay, 1999) and are localized tothe nucleoporin RanBP2/Nup358 also has SUMO1 E3-
cytoplasmic filaments of nuclear pore complexes (NPCs).like activity. RanBP2 directly interacts with the E2 en-
Interestingly, in vivo SUMOylation of specific SUMO1zyme Ubc9 and strongly enhances SUMO1-transfer
targets (Sternsdorf et al., 1999) as well as of an artificialfrom Ubc9 to the SUMO1 target Sp100. The E3-like
reporter protein (Rodriguez et al., 2001) requires theactivity is contained within a 33 kDa domain of RanBP2
presence of an intact nuclear localization signal (NLS).that lacks RING finger motifs and does not resemble
This NLS dependency, in conjunction with enzyme local-PIAS family proteins. Our findings place SUMOylation
ization, has led to the common belief that SUMO1 tar-at the cytoplasmic filaments of the NPC and suggest
gets need to enter the nucleus prior to their modification.that, at least for some substrates, modification and
However, both mamalian RanGAP1 and yeast septinsnuclear import are linked events.
are restricted to the cytoplasmic compartment and are
efficient SUMO1 targets in vivo (Mahajan et al., 1997;Introduction
Matunis et al., 1996; Johnson and Blobel, 1999).
This raises the question of why other targets needSUMO1 (small ubiquitin-related modifier, also known as
an NLS for steady-state modification in vivo. We couldPic1, Ubl1, hSmt3, or sentrin) is only 18% identical to
envisage three equally likely possibilities. First, SUMO1ubiquitin but resembles its structure, its ability to be
modification of some targets may be restricted to the
reversibly ligated to other proteins, and its mechanism
nuclear compartment due to the localization of their
of ligation. More than 30 proteins from different species
specific E3 ligases. Second, SUMO1 modification of
have been identified as SUMOylation substrates, and other targets may take place in the cytoplasm, but they
available data provide compelling evidence for a role of need to enter the nucleus in order to be protected from
SUMO1 in the regulation of protein-protein interactions, isopeptidases. Third, SUMO1 modification may depend
subcellular localization, and stability (reviewed by Hay, on components of the nuclear import machinery.
2001; Melchior, 2000; Mu¨ller et al., 2001). Like ubiquitin, Experiments aimed at understanding SUMO1’s intra-
SUMO1 is attached to targets via an isopeptide bond nuclear localization led us to the discovery that RanBP2
between the C terminus of SUMO1 and the  aminogroup has an E3-like activity in the modification of proteins
of target lysine residues. Ubiquitination of a specific with SUMO1. As RanBP2 is part of the cytoplasmic fila-
target requires three enzymes: an E1 activating enzyme, ments of the NPC and serves as a docking site for import
an E2 conjugating enzyme, and an E3 ligating enzyme complexes (Ben-Efraim and Gerace, 2001; Wu et al.,
(Hershko and Ciechanover, 1998). Only a single ubiquitin 1995; Yaseen and Blobel, 1999; Yokoyama et al., 1995),
E1 has been identified, but multiple E2 and E3 enzymes this suggests that NLS-containing targets for SUMO1
are known. E3 ligases confer substrate specificity and modification can be modified en route to the nucleus.
are highly regulated to ensure that target degradation
occurs only at the appropriate time (reviewed in Jackson Results
et al., 2000; Joazeiro and Weissman, 2000). For SUMO1
modification, a single E1 SUMO1 activating enzyme YFP-SUMO1 Is Intranuclear In Vivo But
Accumulates at the NPC In Vitro
If SUMO1 modification of intranuclear targets was re-3 Correspondence: melchior@biochem.mpg.de
4 These authors contributed equally to this work. stricted to the nuclear compartment, SUMO1 would en-
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ter the nucleus only in unconjugated form. Owing to the nate between active import of free or conjugated
small size of SUMO1 (10 kDa), this could occur by active SUMO1. To investigate this, we carried out in vitro nu-
import or by passive diffusion. Alternatively, if SUMO1 clear import assays (Figure 2). Consistent with our hy-
modification can also precede nuclear import, an en- pothesis that SUMO1 conjugates may be the imported
ergy-dependent mechanism would have to contribute to species in vivo, YFP-SUMO1 (1–97) was not actively
SUMO1 intranuclear accumulation, because most target imported into the nucleus. Instead, it acccumulated at
proteins are too large to enter by diffusion. To test this, the nuclear envelope in a pattern reminiscent of NPC
we used three experimental approaches: first, transfec- staining. Similar results were obtained with FITC-labeled
tion of wt and mutant SUMO1 lacking its C-terminal Gly SUMO (see Supplementary Figure S2 at http://www.cell.
Gly motif; second, microinjection of wt SUMO1 into HeLa com/cgi/content/full/108/1/109/DC1). This rim staining
cells with or without prior ATP depletion; and third, in is temperature sensitive, ATP-dependent, and saturable
vitro nuclear import with digitonin-permeabilized HeLa (unlabeled SUMO1 reduces the signal by competition;
cells. For all three experiments, we chose the same Figure 2B and data not shown). Interestingly, wheat
reporter protein, SUMO1 fused to YFP. GFP-SUMO can germ agglutinin, which inhibits nuclear protein import
replace endogeneous SUMO (pmt3) in fission yeast (Ta- by binding to O-glycosylated NPC proteins (Finlay et al.,
naka et al., 1999), indicating that a GFP-tag or the related 1987), did not significantly inhibit rim staining (FITC-
YFP-tag does not interfere with SUMO1 function in vivo. BSA-NLS import was inhibited; data not shown). This
As shown in Figure 1A, wt YFP-SUMO1 localizes exclu- suggests that YFP-SUMO1 (1–97) accumulates at the
sively in the nucleus after transfection, both diffusely cytoplasmic rather than the nuclear side of the NPC.
distributed in the nucleoplasm and concentrated in nu- Based on the ATP dependence, we speculated that YFP-
clear speckles. In contrast, YFP-SUMO1 (1–95) was dif- SUMO1 was forming isopeptide bonds with NPC-asso-
fusely distributed throughout the cytoplasm and the nu- ciated proteins (thioester bonds could be excluded by
cleus, remarkably similarly to the localization of YFP alone. the resistance of the rim staining to 50 mM DTT; see
This is consistent with previous findings with HA-tagged wt Supplementary Figure S3 at http://www.cell.com/cgi/
and mutant SUMO1 (Mahajan et al., 1998). Immunoblotting content/full/108/1/109/DC1). Indeed, rim staining corre-
(Figure 1B) indicated that a significant proportion of lated under all conditions with the appearance of cell-
YFP-SUMO1 (1–97) was not conjugated to targets at associated YFP-SUMO1 conjugates (Figure 2C). More-
steady-state levels. These findings suggest that an ac- over, incubation of the cells with the S. cerevisiae
tive process concentrates unconjugated YFP-SUMO1 isopeptidase Ulp1 (Li and Hochstrasser, 1999) resulted
(1–97) but not YFP-SUMO1 (1–95) in the nucleus. One in complete loss of rim staining (Figure 2D). In summary,
model consistent with this is cytoplasmic modification these data suggest that accumulation of YFP-SUMO1
of YFP-SUMO1 to targets, active import of the conju- at the nuclear envelope is due to isopeptide bond forma-
gate, and subsequent cleavage by isopeptidases known tion with unknown proteins. This would, however, require
to exist in the nucleus (Hay, 2001; Melchior, 2000; Mu¨ller the presence of SUMO E1 and E2 enzymes in cytosol
et al., 2001). An alternative explanation, noncovalent or at the NPC. Indeed, HeLa cytosol contains significant
nuclear retention requiring the Gly Gly motif in SUMO1, amounts of Aos1 and Ubc9 (see Supplementary Figure
was ruled out by microinjection experiments. For these, S4 at http://www.cell.com/cgi/content/full/108/1/109/
we microinjected YFP-SUMO1 (1–97) into HeLa cells DC1). Therefore, we replaced the cytosol in the assay
and followed its localization over time (Figure 1C and with recombinant Aos1/Uba2 and Ubc9. Both enzymes
Supplementary Figure S1 at http://www.cell.com/cgi/ were expressed in E. coli and purified to near homogene-
content/full/108/1/109/DC1). Only when ATP was present ity (Figure 2E). Addition of these enzymes together with
could YFP-SUMO1 (1–97) become strongly enriched in YFP-SUMO1 (1–97) and ATP is sufficient to generate
the nucleoplasm and in speckles. When ATP was de- strong rim staining in semipermeable cells (Figure 2F),
pleted, YFP-SUMO1 was distributed throughout the
indicating that the modification does not require factors
cells, like mutant SUMO1 upon transfection. Our hy-
provided by the cytosol other than the E1 and E2
pothesis that active import may contribute to SUMO1
enzyme.intranuclear accumulation (either of free SUMO1 or of
conjugates) was further supported by the kinetics of
SUMO1 Chain Formation on RanBP2intranuclear appearance of SUMO1. With ATP, an en-
The rapid SUMO1 modification that appears to takerichment of YFP-SUMO1 (1–97) in the nucleoplasm pre-
place at NPCs suggested the presence of a stimulatoryceded speckle formation and was observed as early
factor, perhaps a SUMO1 E3 ligase. E3 ligases involvedas 1 min after injection. In the absence of ATP, equal
in ubiquitination are often characterized by stable inter-distribution between nucleus and cytoplasm was ob-
actions with E2 enzymes (Jackson et al., 2000; Joazeiroserved only significantly later (Figure 1C and Supple-
and Weissman, 2000), and several ubiquitin E3 ligasesmentary Figure S1 at http://www.cell.com/cgi/content/
are themselves targets for modification (Fang et al.,full/108/1/109/DC1). Finally, to investigate the possibility
2000; Nuber et al., 1998). Two NPC proteins, RanGAP1that SUMO1 conjugation would only take place in the
and RanBP2, are known targets for SUMOylation (Maha-cytoplasm, we also injected YFP-SUMO1 into nuclei of
jan et al., 1997; Matunis et al., 1996; Saitoh et al., 1998),HeLa cells. As is revealed from ATP-dependent speckle
and SUMOylated RanGAP1, RanBP2, and Ubc9 form aformation indicative of conjugates, modification clearly
stable complex in cell extracts (Lee et al., 1998; Saitohcan take place in the nucleus.
et al., 1997, 1998). In contrast to all other known SUMO1Our microinjection data suggest that YFP-SUMO1 en-
targets, RanGAP1 is very efficiently modified both inters the nucleus by both passive diffusion and active
import. These experiments do not allow us to discrimi- vivo and in cell extracts (Mahajan et al., 1997). It is
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Figure 1. Passive Diffusion, Conjugation, and Active Transport Contribute to SUMO1 Intranuclear Accumulation
(A) The C terminus of SUMO1 is necessary for its accummulation in the nucleoplasm and in nuclear speckles. Adherent HeLa cells were
transfected with pEYFP, pEYFP-SUMO1 (1–97), or pEYFP-SUMO1 (1–95) and fixed after 20 hr with 2% formaldehyde. YFP and YFP-fusion
proteins were detected by immunofluorescence microscopy.
(B) HeLa cells transfected as in (A) were harvested after 20 hr in SDS-loading buffer, resolved on a 8% SDS gel, and analyzed by immunoblotting
with  GFP antibodies.
(C) Energy depletion inhibits nuclear accumulation of YFP-SUMO1. YFP-SUMO1 (1–97) (0.4 mg/ml) was microinjected into HeLa cells with or
without prior depletion of ATP. Pictures were taken at indicated time points (injections were all done within times 0 min and 1 min). Arrowheads
mark nuclear injection.
also rapidly and quantitatively modified by recombinant multiple sites. At 30 min, a faint higher molecular weight
smear was apparent, perhaps indicative of additionalAos1/Uba2 and Ubc9 (see Okuma et al., 1999, and be-
low). To test whether RanBP2 can also be modified by conjugates. To investigate this further, we repeated the
time course with an excess of enzymes and SUMO1Aos1/Uba2 and Ubc9 alone, we generated two frag-
ments of RanBP2 (depicted in Figure 3A) that were re- (Figure 3C). Under these conditions, RanGAP1 was
again rapidly modified to a single species. In contrast,ported to contain the necessary determinants for
SUMO1 modification as well as interactions with Gst-BP2 gave rise to multiple bands that increased in
molecular weight during the time course. We infer fromSUMO1*RanGAP1 and Ubc9 (Matunis et al., 1998; Sai-
toh et al., 1998). During the course of this study, we the molar ratios used in this reaction that each Gst-BP2
is modified by up to 25 molecules of SUMO1. As shownfound that the smaller fragment (BP2FG) is sufficient
for the properties described below. Figure 3B shows a in Figure 3D, the extent to which RanBP2 is modified
depends on the molar ratio of Gst-BP2 and SUMO1. Intime course of RanGAP1 (top) and BP2FG (bottom)
modification with recombinant enzymes. Both proteins conclusion, RanBP2 and RanGAP1 can both be effi-
ciently modified with recombinant E1 and E2 enzymes,are clearly modified in this reaction, with RanGAP1 being
converted to a single modified species within just 5 min, but in addition, RanBP2 undergoes an unusual hyper-
modification that leads to depletion of SUMO1 from theand BP2FG being modified somewhat more slowly at
Cell
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Figure 2. Covalent Modification at the NPC
(A) In vitro nuclear import assays with digitonin-permeabilized HeLa cells, cytosol, and 0.8 g YFP-SUMO1 (1–97) were carried out in the
presence (standard) or absence of ATP (addition of 16 U Hexokinase/5 mM glucose). After 30 min at 30C, cells were washed and analyzed
by immunofluorescence microscopy. Identical exposure times were used for “ATP” and “standard” samples. Bottom: equatorial view (left)
and surface view (right) of identical standard cells.
(B) In vitro reactions as in (A) but analyzed by flow cytometry. Ice, incubation at 0C; standard, incubation at 30C; SUMO, reaction in the
presence of 2 g nonfluorescent SUMO1 (1–97); no ATP, 16 U Hexokinase/5 mM glucose; WGA, wheat germ agglutinin (50 g/ml final
concentration) was added to inhibit transport into the nucleus. Gray and white bars indicate duplicate reactions.
(C) Reactions as in (A) but analyzed by immunoblotting. After the reaction, cells were washed twice and lysed in SDS-loading buffer. Samples
were resolved on a 5%–20% SDS gel and analyzed by immunoblotting with  GFP antibodies.
(D) Standard reaction and analysis as in (A), but after washing the sample was split in half and incubated for 20 min at 37C with or without
recombinant isopeptidase (Gst-Ulp1).
(E) Recombinant SUMO1-activating enzyme (Aos1/Uba2) and SUMO1-conjugating enzyme Ubc9, resolved on a 5%–20% SDS gel and stained
by Coomassie blue.
(F) Reaction and analysis as in (A), but with recombinant enzymes (18 g/ml Aos1/Uba2 and 4 g/ml Ubc9) instead of cytosol.
reaction mix. The high-molecular-weight RanBP2-SUMO1 SUMO1 species would be generated by Ulp1. In the
second scenario (SUMO1 chains on Gst-BP2), the cleav-conjugates could potentially form by attachment of sin-
gle SUMO1 entities to multiple lysines in Gst-BP2 or age intermediates could also consist of SUMO1 oligo-
mers. As is apparent from the cleavage pattern, recom-could reflect the formation of SUMO1 chains via
SUMO1-SUMO1 isopeptide bond formation. To distin- binant Ulp1 rapidly generates species with apparent
mobilities of 30, 45, and 60 kDa, indicative ofguish between these two possibilities, we added the
S. cerevisiae isopeptidase Ulp1 to hypermodified Gst- SUMO1 dimers, trimers, and tetramers, and the high-
molecular-weight species disappear. This result is mostBP2 (Figure 3E). In one scenario (multiple attachments of
single SUMO1 molecules to Gst-BP2), only monomeric consistent with the interpretation that SUMO1 forms
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Figure 3. Hypermodification and SUMO1 Chain Formation on RanBP2
(A) Schematic diagram of RanBP2 and constructs used in this study. The 358 kDa RanBP2 contains a leucine-rich domain, a zinc finger
domain, four RanGTP binding domains (R1–R4), a cyclophilin domain (CY), and several FG and FXFG repeats (indicated by short and long
dashes, respectively). I1 and I2 indicate the presence of an internal repeat motif (Wu et al., 1995; Yokoyama et al., 1995).
(B) RanGAP1 and RanBP2 are both efficiently modified with recombinant E1 and E2 enzymes. Recombinant RanGAP1 and BP2FG (500 ng
each) were incubated with SUMO1 (1.5 g), E1 (150 ng), E2 (10 ng), and 5 mM ATP at 37C. Reactions were stopped at indicated time points
with Laemmli-buffer. Proteins were separated on 5%–20% SDS-PAGE, and proteins were stained with Coomassie blue.
(C) Hypermodification of RanBP2. In vitro SUMOylation as in (B), using less substrate (5 ng Gst-BP2 or RanGAP1, 15 ng SUMO1, 150 ng E1,
10 ng E2, and 5 mM ATP) and shorter time points. Detection was by immunoblotting with  SUMO1 antibodies. The arrow indicates SUMO1-
modified RanGAP1, and the asterisk indicates SUMO1-modified Uba2 (T. Bu¨sgen, A.P., and F.M., unpublished results).
(D) Increasing amounts of Gst-BP2 (5–150 ng) were added to an otherwise constant modification mix (15 ng SUMO1, 150 ng E1, 10 ng E2,
and 5 mM ATP) and incubated for 2.5 min at 37C. Detection was by immunoblotting with  SUMO1 antibodies.
(E) Hypermodification of RanBP2 is due to SUMO1 chain formation. Gst-BP2 (5 ng) was hypermodified with 60 ng SUMO1, 150 ng E1, 10 ng
E2, and 0.5 mM ATP for 5 min at 37C. To stop the reaction, ATP was depleted with 1 U apyrase. Gst-Ulp1 isopeptidase was added and
incubated for indicated time points. Reactions were separated by 5%–20% SDS-PAGE, and detection was performed using  SUMO1
antibodies.
chains on RanBP2. SUMO2 is known to form chains E3-like activity. To address this, we relied on our observa-
tion that addition of SUMO1 stimulates modification ofinvolving lysine 11 (Tatham et al., 2001). However, the
SUMO1 chains on RanBP2 seem to be quite different, endogenous proteins in HeLa cytosol. RanGAP1 and
RanBP2 are both present in HeLa cytosol; RanGAP1since a mutant lacking amino acids 1–20 is still compe-
tent for chain formation (M. Schergaut, A.P., and F.M., because it is partially cytoplasmic, and RanBP2 due to
the 5% mitotic cells present in asynchronously growingunpublished data).
cultures. If RanBP2 and/or its binding partner RanGAP1
were indeed required for SUMO1 conjugation, their im-Depletion of RanGAP1/RanBP2 Complexes
Removes SUMOylation Activity from Cytosol munodepletion should lead to a reduction in modifica-
tion. We found that cytosol depleted with  RanGAP1As SUMO1-SUMO1 chain formation was induced in the
presence of RanBP2, we speculated that it may have an antibodies shows a significantly reduced SUMO1 modi-
Cell
114
Figure 4.  RanGAP1 Antibodies Deplete a Stimulatory Activity for SUMOylation from HeLa Cytosol
(A) HeLa cytosol was incubated with  RanGAP1 antibodies or goat preimmunserum (IgG) crosslinked to protein G beads. Supernatants (30
l) were tested for SUMOylation activity by incubation with 60 ng SUMO1 and 5 mM ATP (lanes 1–4). Samples were taken at time 0 and after
1 hr at 30C. Lanes 5–8:  RanGAP1-depleted SN was reconstituted by adding back  RanGAP1 beads (5–6) or IgG beads (7–8) prior to the
reaction. Reactions were resolved on 5%–20% SDS-PAGE and analyzed by immunoblotting with  SUMO1 (top) and  RanGAP1 antibodies
(bottom).
(B) RanGAP1-depleted cytosol is also devoid of RanBP2. Beads and supernatants of the immunoprecipitation in (A) were analyzed by
immunoblotting with  RanBP2,  Aos1,  Ubc9, and  RanGAP1 antibodies.
(C) Reactions were performed as in (A). Cytosol depleted with  RanGAP1 antibodies was complemented with 5 ng recombinant RanGAP1
(lanes 5–6) or 5 ng BP2FG (lanes 7–8).
fication pattern compared to control cytosol (Figure 4A, contrast to RanGAP1, addition of 5 ng BP2FG dramati-
cally stimulated the appearance of SUMO1-modifiedlanes 2 and 4). To verify that this reduction in activity
was caused by depletion rather than inactivation of fac- bands (Figure 4C, lanes 7 and 8). However, the SUMO1
pattern induced by BP2FG is more intense than, andtors, we added back IP beads to RanGAP1-depleted
cytosol. RanGAP1 IP beads but not IgG IP beads re- not identical to, the pattern found in control cytosol.
This is at least in part due to hypermodification of recom-stored most of the activity (Figure 4A, compare lanes 6
and 8). Depletion and readdition of RanGAP1 was veri- binant BP2FG and subsequent cleavage by endogenous
isopeptidases (for comparison, see Figure 3E).fied by immunoblotting with RanGAP1 antibodies (Fig-
ure 4A, bottom). As expected, removal of RanGAP1 by
immunoprecipitation did result in simultaneous deple- RanBP2 Stimulates SUMO1 Modification of Sp100
To fully establish a role for RanBP2 as a stimulator oftion of RanBP2, but importantly neither Ubc9 nor Aos1
levels were affected (Figure 4B). This suggested that SUMO1 modification, we wanted to test its activity with
a well-characterized SUMO1 target. For this we choseRanGAP1, RanBP2, or an unknown associated factor
could be the stimulatory activity that was depleted by Sp100, a component of PML nuclear bodies (Sternsdorf
et al., 1999). This protein seemed an ideal candidate forthe IP. We explored this possibility by adding 5 ng
RanGAP1 or BP2FG to our depleted cytosol (Figure RanBP2-stimulated SUMOylation. It contains a classical
NLS, suggesting that it encounters RanBP2 on its way4C). RanGAP1 was quantitatively modified by the de-
pleted extract (Figure 4C, bottom, lanes 5 and 6), con- into the nucleus. Importantly, this NLS is essential for
modification of Sp100 at lysine 297 in vivo (Sternsdorffirming that E1 and E2 enzymes were still active in the
extracts. However, it did not induce modification of en- et al., 1999). We set up an in vitro modification assay
for Sp100 with recombinant E1 and E2 and tested thedogenous proteins, indicating that RanGAP1 is not the
stimulatory activity (Figure 4C, top, lanes 5 and 6). In effect of BP2FG or full-length RanBP2 from HeLa cells
RanBP2 Has SUMO1 E3 Ligase Activity
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Figure 5. RanBP2 Stimulates In Vitro Modification of the SUMO1 Target Sp100 But Not p53
(A) Both BP2FG and full-length HeLa RanBP2 stimulate SUMOylation of Sp100. In vitro reactions containing 25 ng Gst-Sp100N, 150 ng
E1, 10 ng E2, 60 ng SUMO1, and 5 mM ATP in 20 l reaction volumes were incubated for 1 hr at 30C in the absence or presence of 5 ng
BP2FG or the RanBP2-containing  RanGAP1 immunoprecipitate described in Figure 4B. Samples were analyzed by immunoblotting with
 Gst antibodies. The appearance of two novel bands (arrows) indicate the presence of a major and minor SUMO1 acceptor site in Sp100.
(B) Left: In vitro reactions as in (A) in the absence or presence of increasing concentrations of BP2FG. Right: Reactions with 1.5 g Sp100N,
1.5 g SUMO1, 10 ng E2, 150 ng E1, with or without 5 ng BP2FG.
(C) RanBP2 stimulates modification of Sp100 at the physiological SUMO1 acceptor site. Gst-Sp100N (25 ng) or Gst-Sp100N K297R were
incubated with 600 ng SUMO1, 10 ng E2, 150 ng E1, and 5 mM ATP for 7 min at 30C. Residual modification of the mutant is due to the
presence of a second modification site (see [A] and [B]).
(D) RanBP2 enhances in vitro SUMOylation of Sp100 but not of p53. Reactions with 1 g Gst-Sp100N or Gst-p53, 1.5 g SUMO1, 10 ng E2,
150 ng E1, with or without 5 ng BP2FG.
(provided in the form of RanGAP1 immunoprecipitates shown in Figure 5D, under conditions that allow efficient
modification of Sp100, p53 is not SUMOylated either indescribed in Figure 4). As expected, Aos1/Uba2 and
Ubc9 modify only marginal amounts of Sp100 (Figure the absence or presence of BP2FG. Our recombinant
p53 is competent for modification, as PIASy stimulates5A). This can be significantly increased by the addition
of either BP2FG or full-length RanBP2, demonstrating p53 SUMOylation in similar experiments (A.P., S. Sach-
dev, R. Grossschedl, and F.M., unpublished data). Wethat RanBP2 indeed acts as a stimulator of modification.
We then compared increasing amounts of BP2FG for also tested four novel SUMO1 target proteins; two of
these were better modified in the presence of BP2FG,their effect on Sp100 modification (Figure 5B, left). Al-
ready sufficient for strong stimulation was 1.5 nM and two were not affected (unpublished data). In sum-
mary, RanBP2 appears to work on several but not allBP2FG (1 ng BP2FG per 20 l reaction). Surprisingly,
increasing the concentration of BP2FG actually de- SUMO1 targets. How this specificity is conferred re-
mains to be resolved.creased its efficiency (compare 1 with 20 ng). One possi-
ble explanation for this inverse dose dependence is that
excess BP2FG competes with Sp100 for SUMO1. This RanBP2 Stimulates Transfer of SUMO1
between Ubc9 and Sp100was confirmed in the next experiment (Figure 5B, right),
where we repeated the experiment with a large excess The substrate specificity of RanBP2 already suggests
that it participates in the transfer of SUMO1 from theof Sp100 and SUMO1 (1.5g each of Sp100 and SUMO1,
5 ng BP2FG, 10 ng Ubc9, and 150 ng Aos1/Uba2). In the E2 enzyme to its target. However, from our in vitro data,
we could not exclude the possibility that it functionspresence of BP2FG, Sp100 was nearly quantitatively
modified. RanBP2 stimulates Sp100 modification at its predominantly by enhancing SUMO1 transfer efficiency
between the E1 and the E2 enzyme. We investigatedphysiological SUMO1 attachment site Lys 297 (Sternsdorf
et al., 1999), as is shown in Figure 5C. A faint band visible the step at which it contributes by comparing rates of
Ubc9-SUMO1 thioester bond formation in the absencein the K297R mutant migrates with different mobility than
wt SUMO1*Sp100 and reflects a second, less efficient, or presence of BP2FG (Figure 6A). SUMO1-Ubc9 thio-
esters are formed rapidly and efficiently with or withoutmodification site. A hallmark for E3 ligases is that they
confer substrate specificity. We therefore tested the ability BP2FG. We reproducibly found a modest stimulation
of thioester formation with BP2FG, but the reason forof RanBP2 to stimulate SUMOylation of another well-
known SUMO1 target, the tumor suppressor p53. As this remains to be determined. However, the extremely
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Figure 6. RanBP2 Enhances SUMO1 Transfer from Ubc9 to Sp100
(A) Ubc9-SUMO1 thioester formation in the presence or absence of RanBP2. E2 (100 ng), 150 ng E1, 100 ng SUMO1, and 5 mM ATP were
incubated with or without 1 ng BP2FG at 30C. Reaction was stopped at indicated time points with a nonreducing buffer (DTT) or with a
reducing buffer (DTT). Samples were separated on a 5%–20% SDS gel and analyzed by immunoblotting with  Ubc9.
(B) SUMO1 transfer from Ubc9-SUMO1 thioesters to Sp100 in the presence or absence of RanBP2. E2 (100 ng), 150 ng E1, 100 ng SUMO1,
and 0.5 mM ATP were incubated for 30 min at 30C. After depletion of ATP with 1 U apyrase, 200 ng Gst-Sp100N and 1 ng BP2FG, when
indicated, were added. Reactions were stopped at indicated time points with Laemmli-buffer and separated on a 5%–20% SDS-gel.
(C) A double cysteine mutant of Gst-BP2 is still active in Gst-Sp100N modification. Two cysteines, one in each of two short repeats within
RanBP2, were converted to serine. Modification reactions were carried out as in Figure 5A in the presence of wt Gst-BP2 or Gst-BP2Cys.
Analysis was by immunoblotting with  SP100 antibodies
rapid formation of Ubc9 thioesters indicates that this RanBP2/Ubc9 Interact Transiently
in Sp100 Modificationstep is not rate limiting in our Sp100 modification reac-
tions. Using preformed Ubc9-SUMO1 thioesters, we RanGAP1*SUMO1/RanBP2 and Ubc9 can be found in
a stable complex (Lee et al., 1998; Saitoh et al., 1997),next measured the rate of SUMO1 transfer between
Ubc9 and Sp100. As shown in Figure 6B, BP2FG clearly but it was not known whether Ubc9 binds directly to
RanBP2 or SUMOylated RanGAP1. We tested this byenhances Sp100 modification. The low efficiency com-
pared to the modifications shown in Figure 5 is due to mixing the respective proteins and applying the mixture
to gel filtration (Figure 7A). Surprisingly, Ubc9 could bindthe fact that Ubc9 reloading with SUMO1 was inhibited
by ATP depletion. In conclusion, as expected for an stably to either protein (as well as to unmodified
RanGAP1). Similar findings were also reported by othersE3-like activity, BP2FG does stimulate the transfer of
SUMO1 to its target protein. Ubiquitin E3 ligases depend recently (Saitoh et al., 2001; Sampson et al., 2001). Con-
sidering the stable interaction of RanBP2 with Ubc9on cysteines, either as catalytic residues or as part of
RING finger motifs (Jackson et al., 2000; Joazeiro and and its ability to interact with preformed Ubc9-SUMO1
thioesters, we wanted to test whether RanBP2 functionsWeissman, 2000). The minimal fragment used through-
out this study (BP2FG) contains seven cysteines but as a stable stoichiometric cofactor for Ubc9 or whether
both proteins undergo cycles of association and dissoci-bears no resemblance to RING finger motifs. The only
recognizable motif present in this domain is a short ation during Sp100 modification. In the first scenario,
addition of a stoichiometric complex between RanBP2internal repeat that is conserved in RanBP2s from differ-
ent species. We generated a double mutant (Gst- and Ubc9 should abolish the need for additional Ubc9
under all conditions. In the second scenario, free Ubc9BP2Cys) in which one cysteine in each repeat was
changed to serine. However, this double mutant still concentrations could influence the reaction rate by de-
termining the efficiency of reassociation. We generatedstimulated Sp100 modification (Figure 6C). Alkylating
agents also did not inhibit RanBP2 function (data not two different complexes: a complex consisting just of
BP2FG and Ubc9 (F13), and a complex that also in-shown), suggesting that free cysteine side chains are
not required for its function. These findings open up cluded RanGAP1*SUMO1 to mimic the physiological sit-
uation at the NPC. We first tested 1 l of each complexthe intriguing possibility that the mechanism of RanBP2
activity is different from ubiquitin E3 ligases. (in F9 was an estimated amount of 15 ng BP2FG, 5
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Figure 7. RanBP2 and Ubc9 Interact Only Transiently during Sp100 SUMOylation
(A) Ubc9 binds directly to RanGAP1, SUMO1*RanGAP1, and RanBP2. SUMOylated RanGAP1 (43 g), unmodified RanGAP1 (40 g), or BP2FG
(20 g) were each mixed with an excess of Ubc9 (50 g). After incubation for 1 hr, samples were separated by gel filtration on Superdex 200.
Fractions were analyzed by SDS-PAGE and immunostaining. The asterisk marks residual unmodified RanGAP1.
(B) RanGAP1 (100 g) was modified with SUMO and ATP depleted using a desalting column. RanGAP1*SUMO1 was then incubated with
BP2FG (40 g) and Ubc9 (100g), and the mixture was separated by gel filtration on Superdex 200. Fractions were analyzed by SDS-
PAGE and Coomassie staining. The asterisk marks SUMOylated BP2FG that was generated due to incomplete depletion of ATP. F9,
RanGAP1*SUMO1/BP2FG/Ubc9 complex; F13, BP2FG/Ubc9 complex.
(C) Top: Sp100 modification reactions with 25 ng Gst-Sp100N, 60 ng SUMO1, 150 ng E1, and 5 mM ATP and incubation for 1 hr in the
presence or absence of 1 l fraction 9 (F9) or fraction 13 (F13), with or without addition of 10 ng Ubc9. Bottom: Sp100 modification reactions
with 25 ng Gst-Sp100N, 120 ng SUMO1, 150 ng E1, and 5 mM ATP and incubation for 5 min in the presence or absence of 0.3 l F9 or F13,
with or without addition of 10 ng Ubc9. Analysis was by immunoblotting with  Gst antibodies.
(D) Model: RanBP2 functions as an E3 SUMO1 ligase that couples modification with nuclear import.
ng Ubc9) for its effect on Sp100 modification in 1 hr ciation and dissociation during the reaction. One model
consistent with these observations is that SUMO1-reactions. Both complexes efficiently stimulated Sp100
modification in the absence of additional Ubc9 (Figure loaded Ubc9 binds to RanBP2, transfers SUMO1 to its
target, and dissociates again prior to its reloading by7C, top, compare lanes 3 and 5 or lanes 4 and 6), indicat-
ing that the Ubc9 provided as part of either complex is Aos1/Uba2 (Figure 7D).
catalytically active. We then repeated the experiment
with less complex (0.3l) and a much shorter incubation Discussion
time (5 min). Strikingly, under these conditions, the reac-
tion was clearly dependent on the addition of free Ubc9 RanBP2 Is an E3 SUMO1 Ligase
We have demonstrated here that both full-length(Figure 7C, bottom, compare lanes 3 and 5 or 4 and 6).
The different efficiencies of F9 and F13 appear to be RanBP2 and a 33 kDa fragment of RanBP2 strongly
enhance SUMO1 modification of Sp100 in the presencedue to different levels of BP2FG and Ubc9 in these
fractions, rather than a contribution by RanGAP1 (titra- of recombinant E1 and E2 enzymes. RanBP2 clearly
functions catalytically, as 5 ng BP2FG are sufficient totion experiments, data not shown). In summary, these
findings are not consistent with a model in which Ubc9 induce conversion of a 300-fold molar excess of Sp100
(Figure 5B, right). Does this make RanBP2 a SUMO1 E3and RanBP2 function as a stable complex, but rather
suggest that Ubc9 and RanBP2 undergo cycles of asso- ligase? Ubiquitin E3 ligases are defined as “enzymes
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that bind, directly or indirectly, specific protein sub- at least, this is not the case, since hypermodified
BP2FG still stimulates Sp100 modification (data notstrates and promote the transfer of ubiquitin, directly or
indirectly, from a thioester intermediate to amide link- shown). Interestingly, both classes of SUMO1 E3 ligases
seem to function on many different target proteins. Weages with proteins or polyubiquitin chains” (Hershko and
Ciechanover, 1998). RanBP2 interacts directly with Ubc9 find that RanBP2 stimulates modification of three out
of six tested proteins, and gene disruption of Siz1 andand promotes SUMO1 modification of Sp100 by stimu-
lating transfer of SUMO1 from Ubc9 to Sp100. RanBP2 its relative Siz2 abolishes modification of most targets in
yeast (Johnson and Gupta, 2001). Whether this indicatesdoes not interact directly with Sp100 in pull-down exper-
iments (data not shown) but certainly does interact indi- that SUMOylation involves fewer distinct E3-like factors
than ubiquitination remains to be seen.rectly via Ubc9. Importantly, endogenous RanBP2 at the
NPC will probably also interact with Sp100 by a second
mechanism, due to its role as a docking site in nuclear RanBP2 May Coordinate SUMO1 Modification
protein import. This interaction would be mediated by and Nuclear Import
import receptors that interact with RanBP2 via FG repeat RanBP2 is part of the nucleocytoplasmic transport ma-
domains directly flanking its E3-like domain (Figure 3; chinery (reviewed in Go¨rlich and Kutay, 1999) and serves
Ben-Efraim and Gerace, 2001; Stewart et al., 2001; Ya- as a docking factor for import complexes on their way
seen and Blobel, 1999). Finally, RanBP2 appears to con- into the nucleus. Its dual role in nuclear import and as
fer substrate specificity, since it does stimulate modifi- an E3 ligase agrees well with the observation that a
cation of some but not all SUMO1 targets. Thus, RanBP2 functional NLS is required for SUMOylation of several
fulfills the functional criteria for being an E3 ligase. targets in vivo (Rodriguez et al., 2001, and references
therein). Since RanBP2 is restricted to the NPC in in-
RanBP2 and PIAS SUMO1 E3 Ligases terphase cells, a functional NLS would be required for
Ubiquitin E3 ligases can be classified into two groups efficient target contact with RanBP2.
according to their mode of action (Hershko and Ciecha- SUMO1 modification can clearly take place in the nu-
nover, 1998; Jackson et al., 2000): HECT domain E3 ligases cleus, so why would SUMO1 modification also require
are true enzymes, because they form a thioester bond an E3 ligase at the cytoplasmic phase of the NPC? We
with ubiquitin before they transfer it to their target; a can envision two different possibilities. SUMOylation
second class of E3 ligases, either in the form of individual may be mechanistically involved in the translocation
proteins or as multiprotein complexes, serve as adap- through the NPC. Although intriguing, there is currently
tors between the E2 enzyme and the target. These E3 no evidence for such a function. Alternatively, SUMOyla-
ligases contain RING finger motifs essential for their tion at the NPC may serve as a mechanism to switch
function. RanBP2 does not appear to fall into either proteins from a cytoplasmic to a nuclear mode of action.
group. Treatment of the recombinant protein with alkyl- Placing this at the NPC rather than into the nucleus
ating agents does not inhibit its stimulatory effect on would be more effective and may be particularly impor-
Sp100 modification (data not shown), suggesting that tant for SUMO1 targets that shuttle rapidly between both
thioester bond formation is not required for its activity compartments.
(due to RanBP2’s rapid hypermodification, it has not What are the in vivo targets for RanBP2? For two
been possible to directly test for the appearance of a reasons, we consider it possible that RanBP2 may serve
thioester bond with SUMO1). On the other hand, the to modify many targets on their way into the nucleus.
catalytic domain of RanBP2 (BP2FG) lacks the consen- First, most of the known SUMO1 targets contain a classi-
sus sequence for RING finger domains (Jackson et al., cal NLS and will therefore encounter RanBP2 during
2000), and mutagenesis of two out of seven cysteines their translocation into the nucleus. Second, SUMOyla-
had no effect (no histidines are present in this domain). tion of three out of six proteins was stimulated by
Full-length RanBP2 may serve in part as an adaptor, BP2FG in vitro (Figure 6 and unpublished data). Upon
bringing together NLS-containing target proteins and translocation of modified targets into the nucleus, their
Ubc9. This does not, however, explain the dramatic ef- SUMOylation status could be further regulated by iso-
fect of the isolated BP2FG domain. We consider it most peptidases as well as by E1, E2, and E3 modifying en-
likely that BP2FG functions allosterically by increasing zymes that reside inside the nucleus.
Ubc9’s affinity for specific targets or by facilitating In conclusion, we have provided compelling evidence
SUMO1 transfer to specific lysine residues. that the NPC protein RanBP2 has SUMO1 E3 ligase
RanBP2 is clearly distinct from PIAS E3 ligases (John- activity. Together with RanBP2’s well-established role
son and Gupta, 2001; Kahyo et al., 2001; Sachdev et as a docking site for transport complexes, this suggests
al., 2001; Takahashi et al., 2001), both by amino acid that, at least for some SUMO1 targets, modification and
sequence and due to the fact that PIAS—but not nuclear import are coordinated events.
RanBP2—catalytic activity depends on a RING-like
domain. Experimental Procedures
Common to both is their ability to stimulate SUMO
Plasmidschain formation. RanBP2 forms chains on itself, while
pEYFP-SUMO (1–97) and pEYFP-SUMO (1–101) were generated bySiz1 induces free SUMO chains as well as chains on
amplification of SUMO1 expression plasmids (Mahajan et al., 1998)targets (our data; Johnson and Gupta, 2001). The physi-
and subsequent cloning into the BamHI/KpnI sites of pEYFP (Clon-
ological relevance for this, however, is not yet clear. An tech). pEYFP-SUMO (1–95) was made by introduction of a stop
exciting function for RanBP2 chain formation would be codon in pEYFP-SUMO (1–101) through mutagenesis. For protein
expression, YFP-SUMO (1–97) was recloned into the NcoI/BamHIautoinhibition of its catalytic activity. However, in vitro,
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site of pET11d (Novagen). For expression of untagged SUMO1 ultracentrifugation for 1 hr followed. Aliquots were stored at 80C.
Cytosol preparation for in vitro modification assays and immunopre-(1–97), SUMO1 (197) cDNA was amplified by PCR and cloned
into the NdeI and BamHI sites of pET11a. Human Uba2 cDNA was cipitations involved cell lysis by hypotonic swelling and douncing
and was essentially as in Melchior (1998). The final step involvedamplified by PCR from EST clone DKFZp434DO717 and cloned into
NcoI and BamHI sites of pET11d. Human Aos1 cDNA was PCR chromatography over a desalting column (PD10, Amersham Phar-
macia) in TB.amplified from EST clone DKFZp434J0913 and cloned into NheI and
BamHI sites of pET28a. Mouse Ubc9 cDNA was amplified by PCR For immunoprecipitation, 1 mg affinity-purified goat  RanGAP1
antibody and goat IgGs were each crosslinked to 0.5 ml Ultralinkfrom EST clone number IMAGp998A061122 and cloned into NdeI
and BamHI sites of pET23a. Expression clones for Gst-RanBP2 TM Immobilized Protein G Plus beads (PIERCE) using dimethylpi-
melimidate (PIERCE) as crosslinker. After 1 hr preclearing with pre-(aa 2503–2893) and Gst-RanBP2FG (aa 2553–2838) were obtained
through PCR from human RanBP2 cDNA (a kind gift by Dr. Takeharu immunserum, 1 ml cytosolic extracts were either incubated with 100
l crosslinked anti-RanGAP1 or 100 l crosslinked IgG for 2 hr atNishimoto) and cloning into the BamHI/EcoRI sites of pGEX3X
(Amersham Pharmacia Biotechnology). A plasmid for Gst- 4C. After centrifugation, beads were washed four times with TB
containing protease inhibitors and 1 mM DTT.RanBP2Cys (Cys2659Ser and Cys2737Ser) was obtained through
site-directed mutagenesis. A plasmid for Gst-SP100 (aa 187–480)
was obtained by cloning a MscI-EcoRI fragment from SP100 cDNA In Vitro SUMOylation Assay
(Seeler et al., 2001) into the SmaI and EcoRI sites of pGEX-3X. Gst- SUMO1 modification assays were performed in a total volume of
SP100 (187–480, K297R) was obtained by site-directed mutagene- 20 l in TB with protease inhibitors and 1 mM DTT. Reactions con-
sis. pET11d-RanGAP1 was described previously (Mahajan et al., taining low concentrations of recombinant enzymes were supple-
1997). Expression plasmids for Gst-Ulp1 and GST-p53 were kindly mented with 0.05% Tween and 0.2 mg/ml Ovalbumin Grade VI
provided by Dr. Mark Hochstrasser (Li and Hochstrasser, 1999) and (SIGMA). Reactions were incubated at 30C or 37C and were
Dr. Moshe Oren, respectively. stopped by addition of Laemmli-buffer. Protein concentrations were
as indicated in the figure legends. Thioester reactions were per-
formed in 20 mM Tris (pH 7.6), 50 mM NaCl, 10 mM MgCl2, proteaseExpression and Purification of Recombinant Proteins
inhibitors, and 0.1 mM DTT. Reactions were terminated by 1:1 dilu-Unless stated otherwise, all protein purification protocols involved
tion with 2	 nonreducing sample buffer (50 mM Tris [pH 6.8], 2%IPTG-induced expression in E. coli BL21 gold (Stratagene), bacterial
SDS, 4 M urea, 10% glycerol).lysis with lysozyme, and a 100,000	 g spin for 1 hr to collect soluble
proteins. Each buffer contained 1g/ml each of leupeptin, pepstatin,
In Vitro Nuclear Import, Transfection, and Microinjectionand aprotinin, and 1 mM DTT (or 
-mercapto ethanol); lysis buffers
Cultivation of HeLa suspension cells, in vitro import assays, andalso contained 0.1 mM PMSF. After specific purification steps de-
quantitation by flow cytometry were essentially as described (Mel-scribed below, proteins were aliquoted, flash frozen, and stored
chior, 1998). YFP-SUMO1 (1–97) (0.8g) was used per 40l reaction.at 80C. The final buffer in each protocol was transport buffer (TB:
Pictures were taken using a Zeiss Axioskop II and a MicroMax CCD20 mM HEPES, 110 mM K-acetate, 2 mM Mg-acetate, 0.5 mM EGTA).
camera (Princeton Instruments). Transfection of adherent HeLa cellsGst-fusion proteins followed standard protocols and included dial-
was carried out with Superfect transfection reagent according toysis against TB as the final step. Pure BP2FG and BP2Cys were
manufacturer’s instructions (Qiagen). After 20 hr, cell were fixedobtained by factor Xa cleavage according to the manufacturer’s
with 2% paraformaldehyde for 10 min and analyzed by immunofluo-protocol (Novagen), removal of Gst by glutathion sepharose, and
rescence, or where harvested, were lysed with SDS-loading buffermolecular sieving (Superdex 200, Pharmacia). Purification of
and analyzed by immunoblotting. Microinjection of YFP-SUMO1RanGAP1 was as described previously (Mahajan et al., 1997).
(1–97) was into adherent HeLa cells. ATP depletion was accom-SUMO1 purification involved bacterial lysis in 50 mM Tris/HCl (pH
plished by incubating the cells for 30 min in glucose-free DMEM8), 50 mM NaCl by sonification, preclearing of the 100,000 	 g
(GIBCO) supplemented with 10% FBS, 6 mM 2-deoxyglucose, andsupernatant with Q sepharose (SIGMA), concentration, and subse-
10 mM sodium azide. Cells were kept at 37C, and pictures werequent gel filtration. YFP-SUMO1 (1–97) purification involved lysis in
taken at different times after injection using an inverted microscope50 mM Tris/HCl (pH 8), 100 mM NaCl, 1 mM EDTA, ultracentrifuga-
with CCD camera (Olympus IX70).tion, ion exchange chromatography (HightrapQ, Amersham Phar-
macia), and molecular sieving. Purification of SUMO E1 enzyme
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